{"id":"W3017322331","doi":"10.1016/j.jtho.2020.03.028","title":"Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":607,"is_retracted":false,"has_abstract":true,"ca_institutions":"William Osler Health System","funders":"Eli Lilly Japan; Incyte; Yuhan; F. Hoffmann-La Roche; Roche; Chugai Pharmaceutical; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Atezolizumab; Medicine; Carboplatin; Hazard ratio; Internal medicine; Oncology; Population; Paclitaxel; Randomized controlled trial; Chemotherapy; Confidence interval; Cancer; Cisplatin; Pembrolizumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002075017,0.0009492994,0.001649511,0.0002561217,0.0002486987,0.0008880647,0.0007909261,0.0009109045,0.004182286],"category_scores_gemma":[0.0019868,0.0004066626,0.001679968,0.0003349712,0.0006487382,0.0008562563,0.0004442864,0.002290442,0.0004924369],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006356112,"about_ca_system_score_gemma":0.00102957,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000429275,"about_ca_topic_score_gemma":0.001377287,"domain_scores_codex":[0.9994504,0.0003159545,0.0000415785,0.00007652526,0.00006346848,0.00005209098],"domain_scores_gemma":[0.9991229,0.0002352409,0.0002380601,0.00008011289,0.00006147115,0.0002622105],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9182342,0.01045039,0.003001,0.001231201,0.002307152,0.00007772273,0.00007647369,0.0007868102,0.005398334,0.0002388765,0.003206872,0.05499107],"study_design_scores_gemma":[0.9212677,0.06986539,0.004707636,0.00007222779,0.001115984,0.000103758,0.00002288126,0.0006907847,0.0005553851,0.0001718138,0.001410311,0.00001612247],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9853911,0.007068061,0.0005389673,0.0009331278,0.0002531631,0.002154938,0.001311874,0.0000828902,0.002265965],"genre_scores_gemma":[0.9838828,0.004336687,0.001905297,0.001506591,0.0003430911,0.002935075,0.003183617,0.00002711466,0.001879635],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004182286,"threshold_uncertainty_score":0.01399112,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02215734906571848,"score_gpt":0.3832901829427656,"score_spread":0.3611328338770471,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}